Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: A meta-analysis

European Journal of Cancer

Volumn 51, Issue 5, 2015, Pages 587-594

  Pietrantonio, Filippo ^a   Petrelli, Fausto ^b   Coinu, Andrea ^b   Di Bartolomeo, Maria ^a   Borgonovo, Karen ^b   Maggi, Claudia ^a   Cabiddu, Mary ^b   Iacovelli, Roberto ^a   Bossi, Ilaria ^a   Lonati, Veronica ^b   Ghilardi, Mara ^b   De Braud, Filippo ^a   Barni, Sandro ^b  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b TREVIGLIO HOSPITAL   (Italy)

Author keywords

BRAF mutation; Cetuximab; Colorectal cancer; Meta analysis; Panitumumab

Indexed keywords

B RAF KINASE; CETUXIMAB; PANITUMUMAB; ANTINEOPLASTIC AGENT; BRAF PROTEIN, HUMAN; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; MONOCLONAL ANTIBODY; PROTEIN KINASE INHIBITOR; RAS PROTEIN;

ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; COLORECTAL CANCER; DRUG EFFICACY; GENE MUTATION; HAZARD RATIO; HUMAN; META ANALYSIS; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); ANTAGONISTS AND INHIBITORS; CHI SQUARE DISTRIBUTION; COLORECTAL NEOPLASMS; DISEASE COURSE; DISEASE FREE SURVIVAL; ENZYMOLOGY; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; MORTALITY; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; PERSONALIZED MEDICINE; RISK; RISK FACTOR; TIME; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CHI-SQUARE DISTRIBUTION; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; HUMANS; INDIVIDUALIZED MEDICINE; MOLECULAR TARGETED THERAPY; MUTATION; ODDS RATIO; PREDICTIVE VALUE OF TESTS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84925105975     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2015.01.054     Document Type: Review

References (42)

1. W.S. Samowitz, H. Albertsen, and C. Sweeney et al. Association of smoking, CpG island methylator phenotype, and V600E BRAF mutations in colon cancer J Natl Cancer Inst 98 23 2006 1731 1738
2. B. Tran, S. Kopetz, and J. Tie et al. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer Cancer 117 20 2011 4623 4632
3. T. Joyce, E. Oikonomou, and V. Kosmidou et al. A molecular signature for oncogenic BRAF in human colon cancer cells is revealed by microarray analysis Curr Cancer Drug Targets 12 7 2012 873 898
4. V. Popovici, E. Budinska, and S. Tejpar et al. Identification of a poor-prognosis BRAF-mutant-like population of patients with colon cancer J Clin Oncol 30 12 2012 1288 1295
5. J. Tol, I.D. Nagtegaal, and C.J. Punt BRAF mutation in metastatic colorectal cancer N Engl J Med 361 1 2009 98 99
6. J. Souglakos, J. Philips, and R. Wang et al. Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer Br J Cancer 101 3 2009 465 472
7. E. Van Cutsem, C.H. Köhne, and I. Láng et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status J Clin Oncol 29 15 2011 2011 2019
8. C. Bokemeyer, I. Bondarenko, and J.T. Hartmann et al. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study Ann Oncol 22 7 2011 1535 1546
9. W.L. Ince, A.M. Jubb, and S.N. Holden et al. Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab J Natl Cancer Inst 97 13 2005 981 989
10. S.D. Richman, M.T. Seymour, and P. Chambers et al. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial J Clin Oncol 27 35 2009 5931 5937
11. F. Di Nicolantonio, M. Martini, and F. Molinari et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer J Clin Oncol 26 35 2008 5705 5712
12. F. Perrone, A. Lampis, and M. Orsenigo et al. PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients Ann Oncol 20 1 2009 84 90
13. W. De Roock, B. Claes, and D. Bernasconi et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis Lancet Oncol 11 8 2010 753 762
14. J.Y. Douillard, K.S. Oliner, and S. Siena et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer N Engl J Med 369 11 2013 1023 1034
15. C. Bokemeyer, E. Van Cutsem, and P. Rougier et al. Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials Eur J Cancer 48 10 2012 1466 1475
16. M.K. Parmar, V. Torri, and L. Stewart Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints Stat Med 17 24 1998 2815 2834
17. C.S. Karapetis, D. Jonker, and M. Daneshmand et al. PIK3CA, BRAF, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer-results from NCIC CTG/AGITG CO.17 Clin Cancer Res 20 3 2014 744 753
18. C.G. Smith, D. Fisher, and B. Claes et al. Somatic profiling of the epidermal growth factor receptor pathway in tumors from patients with advanced colorectal cancer treated with chemotherapy ± cetuximab Clin Cancer Res 19 15 2013 4104 4113
19. M.T. Seymour, S.R. Brown, and G. Middleton et al. Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial Lancet Oncol 14 8 2013 749 759
20. M. Peeters, K.S. Oliner, and A. Parker et al. Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer Clin Cancer Res 19 7 2013 1902 1912
21. K.M. Tveit, T. Guren, and B. Glimelius et al. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study J Clin Oncol 30 15 2012 1755 1762
22. M. Peeters, K.S. Oliner, and T.J. Price et al. Updated analysis of KRAS/NRAS and BRAF mutations in study 20050181 of panitumumab (pmab) plus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC) J Clin Oncol 32 Suppl. 5 2014 abstr 3568
23. S. Stintzing, A. Jung, and L. Rossius et al. Mutations within the EGFR signaling pathway: Influence on efficacy in FIRE-3-A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients J Clin Oncol 32 Suppl. 3 2014 abstr 445
24. E. Oikonomou, E. Makrodouli, and M. Evagelidou et al. BRAF(V600E) efficient transformation and induction of microsatellite instability versus KRAS(G12V) induction of senescence markers in human colon cancer cells Neoplasia 11 2009 1116 1131
25. I.J. Kim, H.C. Kang, S.G. Jang, K. Kim, S.A. Ahn, and H.J. Yoon et al. Oligonucleotide microarray analysis of distinct gene expression patterns in colorectal cancer tissues harboring BRAF and K-ras mutations Carcinogenesis 27 2006 392 404
26. H. Kikuchi, M.S. Pino, M. Zeng, S. Shirasawa, and D.C. Chung Oncogenic KRAS and BRAF differentially regulate hypoxia-inducible factor-1alpha and -2alpha in colon cancer Cancer Res 69 2009 8499 8506
27. I.H. Sahin, S.M. Kazmi, and J.T. Yorio et al. Rare though not mutually exclusive: a report of three cases of concomitant KRAS and BRAF mutation and a review of the literature J Cancer 4 4 2013 320 322
28. J.R. Bledsoe, M. Kamionek, and M. Mino-Kenudson BRAF V600E immunohistochemistry is reliable in primary and metastatic colorectal carcinoma regardless of treatment status and shows high intratumoral homogeneity Am J Surg Pathol 38 10 2014 1418 1428
29. D. Cui, D. Cao, and Y. Yang et al. Effect of BRAF V600E mutation on tumor response of anti-EGFR monoclonal antibodies for first-line metastatic colorectal cancer treatment: a meta-analysis of randomized studies Mol Biol Rep 41 3 2014 1291 1298
30. C. Therkildsen, T.K. Bergmann, and T. Henrichsen-Schnack et al. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: a systematic review and meta-analysis Acta Oncol 53 7 2014 852 864
31. Z.X. Yuan, X.Y. Wang, and Q.Y. Qin et al. The prognostic role of BRAF mutation in metastatic colorectal cancer receiving anti-EGFR monoclonal antibodies: a meta-analysis PLoS One 8 6 2013 e65995
32. F. Loupakis, C. Cremolini, and L. Salvatore et al. FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer Eur J Cancer 50 1 2014 57 63
33. F. Loupakis, C. Cremolini, and G. Masi et al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer N Engl J Med 371 17 2014 1609 1618
34. A. Prahallad, C. Sun, and S. Huang et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR Nature 483 7387 2012 100 103
35. R.B. Corcoran, H. Ebi, and A.B. Turke et al. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib Cancer Discov 2 3 2012 227 235
36. S. Kopetz et al. PLX4032 in metastatic colon cancer patients with mutant BRAF tumors J Clin Oncol 28 Suppl. 15 2010 abstr 3534
37. R.B. Corcoran, G.S. Falchook, and J.R. Infante et al. BRAF V600 mutant colorectal cancer (CRC) expansion cohort from the phase I/II clinical trial of BRAF inhibitor dabrafenib (GSK2118436) plus MEK inhibitor trametinib (GSK1120212) J Clin Oncol 30 Suppl. 5 2012 abstr 3528
38. L. Liu, H. Shi, and M.R. Bleam et al. Antitumor effects of dabrafenib, trametinib, and panitumumab as single agents and in combination in BRAF-mutant colorectal carcinoma (CRC) models J Clin Oncol 32 Suppl. 5 2014 abstr 3513
39. J.C. Bendell, C.E. Atreya, and T. André et al. Efficacy and tolerability in an open-label phase I/II study of MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in combination in patients (pts) with BRAF V600E mutated colorectal cancer (CRC) J Clin Oncol 32 Suppl. 5 2014 abstr 3515
40. J. Tabernero, E. Chan, and J. Baselga et al. VE-BASKET, a Simon 2-stage adaptive design, phase II, histology-independent study in nonmelanoma solid tumors harboring BRAF V600 mutations (V600m): Activity of vemurafenib (VEM) with or without cetuximab (CTX) in colorectal cancer (CRC) J Clin Oncol 32 Suppl. 5 2014 abstr 3518
41. R. Van Geel, E. Elez, and J.C. Bendell et al. Phase I study of the selective BRAFV600 inhibitor encorafenib (LGX818) combined with cetuximab and with or without the á-specific PI3K inhibitor BYL719 in patients with advanced BRAF-mutant colorectal cancer J Clin Oncol 32 Suppl. 5 2014 abstr 3514
42. D.S. Hong, V.K. Morris, and S. Fu et al. Phase 1B study of vemurafenib in combination with irinotecan and cetuximab in patients with BRAF-mutated advanced cancers and metastatic colorectal cancer J Clin Oncol 32 Suppl. 5 2014 abstr 3516